Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.

Cancer science - 1 Aug 2026

Oda Katsutoshi, Shintani Daisuke, Nishijima Akira, Mori Mayuyo, Kato Kazuyoshi, Nagao Shoji, Matsumura Noriomi, Kagabu Masahiro, Takenaka Masataka, Yoshihara Kosuke, Konno Yosuke, Hamanishi Junzo, Sato Sho, Takamatsu Shiro, Ueda Keiko, Kashiwabara Kosuke, Aoki Takashi, Nishimura Kunihiro, Tatsuno Kenji, Aburatani Hiroyuki, Hasegawa Kosei

Abstract excerpt

We aimed to develop the mutational signature-based BioMarker (MSBM) to define homologous recombination deficiency (HRD) in newly diagnosed, advanced ovarian cancer and overcome limitations of genomic scar-based assays. We conducted a phase 2 trial (MSBM-OL) to evaluate the efficacy of olaparib maintenance monotherapy and to validate MSBM as a novel HRD biomarker. The MSBM was designed to integrate three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exome Sequencing
Share to Homologous Recombination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Maintenance Chemotherapy

Share to Neoplasm Grading

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 42178168
DOI: 10.1111/cas.70421
PMCID: PMC13394926

Genes

CCNE1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.PMID 42178168Read ↗

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian CancerSemantic proximity Read ↗

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?Semantic proximity Read ↗

Benchmarking homologous recombination deficiency algorithms for prediction of clinical outcome in ovarian cancerSemantic proximity Read ↗

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancerSemantic proximity Read ↗

Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment.Semantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian CancerSemantic proximity Read ↗

Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.Semantic proximity Read ↗

Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.Semantic proximity Read ↗

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer DiagnosisSemantic proximity Read ↗

Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinomaSemantic proximity Read ↗

HRDetect in Ovarian Carcinoma: Stratification and Therapeutic ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.